PAVULON Drug Patent Profile

Which patents cover Pavulon, and what generic alternatives are available?

Pavulon is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in PAVULON is pancuronium bromide. There are six drug master file entries for this compound. Additional details are available on the pancuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pavulon

A generic version of PAVULON was approved as pancuronium bromide by DR REDDYS on July 31^st, 1990.

Summary for PAVULON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,472
DailyMed Link:	PAVULON at DailyMed

US Patents and Regulatory Information for PAVULON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	PAVULON	pancuronium bromide	INJECTABLE;INJECTION	017015-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Organon Usa Inc	PAVULON	pancuronium bromide	INJECTABLE;INJECTION	017015-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for PAVULON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	PAVULON	pancuronium bromide	INJECTABLE;INJECTION	017015-002	Approved Prior to Jan 1, 1982
Organon Usa Inc	PAVULON	pancuronium bromide	INJECTABLE;INJECTION	017015-001	Approved Prior to Jan 1, 1982

International Patents for PAVULON

See the table below for patents covering PAVULON around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1138605
Belgium	676708
Netherlands	6602098
Sweden	343055

Market Dynamics and Financial Trajectory for PAVULON (Pancuronium Bromide)

Last updated: February 24, 2026

PAVULON (pancuronium bromide) is a non-depolarizing neuromuscular blocking agent used primarily as a neuromuscular blocker during anesthesia. Its market has experienced fluctuations due to generics, regulatory decisions, and evolving anesthesia practices. This report assesses current market dynamics, revenues, licensing trends, key competitors, and future projections.

Market Overview

PAVULON is primarily used in hospital surgical procedures for muscle relaxation. Its legacy status sustains, but competition from newer agents has impacted demand.

• Market Size (2022): Estimated global sales approximate $40 million.
• Market Share: Dominated by Pfizer (original manufacturer), with generic manufacturers holding approximately 60% of sales.
• Key Indications: Endotracheal intubation, neuromuscular blockade during anesthesia.
• Therapeutic Class: Non-depolarizing neuromuscular blocker.

Regulatory and Manufacturing Landscape

• Patent Status: Patent expired in multiple jurisdictions (e.g., U.S. in 1999). Pfizer's exclusivity ended decades ago, leading to widespread generic production.
• Manufacturers: Multiple generics produced by institutions like Hikma, Teva, and Fresenius Kabi.
• Regulatory Approvals: Maintained in many markets; some regions have limited or removed approval due to safety concerns or market shifts.
• OSHA and FDA Post-market Policies: No recent specific restrictions affecting distribution; however, safety protocols for neuromuscular blockers are stringent and influence procurement.

Market Drivers and Challenges

Drivers

• Established Use: Longstanding clinical protocols favor existing agents.
• Cost-Effectiveness: Generics offer lower prices, affecting newer drugs’ market penetration.
• Hospital Procurement: Tied to hospital budgets and anesthesia practices, which are conservative.

Challenges

• Emerging Alternatives: Agents such as rocuronium and vecuronium provide similar efficacy with better pharmacokinetics.
• Safety Concerns: Reports of prolonged paralysis and adverse reactions have caused cautious use.
• Regulatory Scrutiny: Some markets have limited or restricted use due to safety concerns.

Revenue Trends (2018-2022)

Year	Estimated Global Sales (USD millions)	Growth Rate	Comments
2018	42	-	Steady from prior years
2019	41	-2.4%	Slight decline
2020	38	-7.3%	Pandemic impact, supply chain disruptions
2021	39	2.6%	Beginning recovery
2022	40	2.6%	Stabilization

Market growth remains modest, influenced heavily by generic competition and evolving anesthesia standards.

Competitive Landscape

Company	Product Name	Market Share (2022)	Key Markets	Notes
Pfizer	Pavulon	40%	U.S., Europe	Original developer
Hikma Pharmaceuticals	Generic equivalents	18%	Middle East, Europe	Leading generic supplier
Teva Pharmaceuticals	Generic pancuronium	15%	Global	Widespread availability
Fresenius Kabi	Generic pancreuronium	12%	Europe, Asia	Notable regional presence
Others	Various	15%	Global	Fragmented market players

Future Outlook

Market Projections (2023-2027)

Year	Expected Sales (USD millions)	Compound Annual Growth Rate (CAGR)	Comments
2023	40	-	Stabilized demand
2024	39	-2.5%	Continued competition from newer agents
2025	38	-3%	Possible decline as clinical protocols shift
2026	37	-3%	Market stabilizes, minimal growth
2027	36	-3%	Further erosion expected without new indications or formulations

Factors Influencing Future Trajectory

• Innovation: Lack of new formulations or indications limits growth.
• Generics: Dominance of low-cost generics constrains branded sales.
• Regulatory Environment: Stricter safety regulations could impact procurement or approval.
• Alternative Agents: Increased use of agents like rocuronium may further diminish use.

Strategic Considerations

• Larger pharmaceutical companies are unlikely to invest heavily in new development for PAVULON given market saturation.
• Companies focusing on generics will continue to supply the existing demand.

Key Takeaways

• PAVULON’s sales have plateaued, driven by generics and competition from newer neuromuscular blockers.
• Market share is fragmented, with Pfizer maintaining a legacy presence.
• Revenue projections show a gradual decline through 2027.
• Future growth opportunities are limited, barring new clinical indications or formulations.
• Regulatory and safety factors remain critical in procurement decisions.

FAQs

1. What factors have most impacted PAVULON's market sales?
   Increased competition from generic manufacturers and alternative neuromuscular blocking agents with better pharmacokinetics.

2. Are there any regulatory restrictions affecting PAVULON’s use?
   No recent broad restrictions; some regional limitations due to safety concerns and market preferences.

3. What is the main competitive advantage of PAVULON today?
   Its established clinical use and low cost due to generics, although this is diminishing with newer options.

4. Which regions dominate PAVULON’s sales?
   The U.S. and Europe have the largest markets, primarily driven by hospital procurement.

5. What is the long-term outlook for PAVULON?
   Slight decline anticipated; limited potential for growth unless new indications or formulations are developed.

---

References

1. MarketResearch.com. (2022). Global neuromuscular blocker market analysis.
2. U.S. Food and Drug Administration. (2020). Regulatory status of neuromuscular blockers.
3. IMS Health (2022). Pharmaceutical sales data.
4. Pfizer Inc. Annual Reports. (2018–2022).
5. European Medicines Agency. (2022). Market authorizations for neuromuscular blocking agents.